Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

Inclusion Criteria Patients must have: * HIV seropositivity. * Absolute CD4 count of 200 - 500 cells/mm3. * No active opportunistic infection or Kaposi's sarcoma. Prior Medication: Allowed: * Prior ddI for no longer than 3 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Lymphoid malignancy. * Pancreatitis. * Peripheral neuropathy. * Critical illness. Concurrent Medication: Excluded: * Antiretroviral agents other than ddI. * Steroids. * Cytotoxic agents. * Immunosuppressive agents. * Immunomodulators. * 1-Thyroxine. Concurrent Treatment: Excluded: * Radiotherapy. Prior Medication: Excluded within 1 month prior to study entry: * Antiretroviral agents other than ddI (patients may have received prior ddI for no longer than 3 months total). * Steroids. * Cytotoxic agents. * Immunosuppressive agents. * Immunomodulators. Prior Treatment: Excluded: * Radiotherapy within 1 month prior to study entry. Active drug abuse.